Firebrick Pharma Extends Agreement to Boost Asian Sales

Firebrick Pharma Limited (AU:FRE) has released an update.

Firebrick Pharma Ltd has extended its consulting agreement with Keith Shortall to boost sales of Nasodine in Singapore and explore partnerships across Asia. The six-month extension, starting in January 2025, includes a grant of 1.5 million share options to Shortall, contingent on meeting specific sales and partnership targets. This move signals Firebrick’s strategic push to strengthen its presence in the Asian pharmaceutical market.

For further insights into AU:FRE stock, check out TipRanks’ Stock Analysis page.